03682nam 2200589Ia 450 991083052460332120230725025103.03-527-63212-31-282-78383-197866127838383-527-63003-13-527-63004-X(CKB)2670000000047583(EBL)584980(OCoLC)670411405(SSID)ssj0000456796(PQKBManifestationID)11303031(PQKBTitleCode)TC0000456796(PQKBWorkID)10409606(PQKB)10336058(MiAaPQ)EBC584980(EXLCZ)99267000000004758320100303d2010 uy 0engur|n|---|||||txtccrAnalogue-based drug discovery II[electronic resource] /edited by Janos Fischer and C. Robin GanellinWeinheim Wiley-VCHc20101 online resource (566 p.)Description based upon print version of record.3-527-32549-2 Includes bibliographical references and index.Analogue-based Drug Discovery II; Contents; Preface; Introduction; Abbreviations; Part I: General Aspects; 1 Optimizing Drug Therapy by Analogues; 2 Standalone Drugs; 3 Application of Molecular Modeling in Analogue-Based Drug Discovery; 4 Issues for the Patenting of Analogues; Part II: Analogue Classes; 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes; 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction; 7 Rifamycins, Antibacterial Antibiotics and Their New Applications; 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs9 Anthracyclines, Optimizing Anticancer Analogues10 Paclitaxel and Epothilone Analogues, Anticancer Drugs; 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression; 12 Muscarinic Receptor Antagonists in the Treatment of COPD; 13 ß-Adrenoceptor Agonists and Asthma; Part III: Case Histories; 14 Liraglutide, a GLP-1 Analogue to Treat Diabetes; 15 Eplerenone: Selective Aldosterone Antagonist; 16 Clevudine, to Treat Hepatitis B Viral Infection; 17 Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-118 Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV19 Lapatinib, an Anticancer Kinase Inhibitor; 20 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia; 21 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder; IndexBorn out of a project of the IUPAC's committee on Medicinal Chemistry and Drug Development, this reference addresses past and current strategies for successful drug analog development, extending the previously published volume by nine new analog classes and eight case studies. Like its precursor, this volume also contains a general section discussing universally applicable strategies for analog discovery and development. Spanning a wide range of therapeutic fields and chemical classes, the two volumes together constitute the first systematic approach to drug analog development.Of interest Drug developmentDrugsDesignDrug development.DrugsDesign.615.19Fischer János881301Ganellin C. R(C. Robin)881302MiAaPQMiAaPQMiAaPQBOOK9910830524603321Analogue-based drug discovery II3937402UNINA